Smart Money Group LLC Sells 1,593 Shares of Novo Nordisk A/S (NYSE:NVO)

Smart Money Group LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 21.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,829 shares of the company’s stock after selling 1,593 shares during the period. Smart Money Group LLC’s holdings in Novo Nordisk A/S were worth $501,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Annex Advisory Services LLC grew its position in shares of Novo Nordisk A/S by 4.5% during the 4th quarter. Annex Advisory Services LLC now owns 5,052 shares of the company’s stock worth $435,000 after buying an additional 219 shares during the period. My Legacy Advisors LLC grew its holdings in Novo Nordisk A/S by 2.9% during the 4th quarter. My Legacy Advisors LLC now owns 7,029 shares of the company’s stock worth $583,000 after acquiring an additional 201 shares during the period. Liberty One Investment Management LLC raised its position in shares of Novo Nordisk A/S by 27.9% during the 4th quarter. Liberty One Investment Management LLC now owns 2,373 shares of the company’s stock valued at $204,000 after acquiring an additional 517 shares during the last quarter. Romano Brothers AND Company lifted its stake in shares of Novo Nordisk A/S by 12.0% in the 4th quarter. Romano Brothers AND Company now owns 6,328 shares of the company’s stock valued at $544,000 after purchasing an additional 680 shares during the period. Finally, Aaron Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S by 6.9% in the 4th quarter. Aaron Wealth Advisors LLC now owns 21,572 shares of the company’s stock worth $1,856,000 after purchasing an additional 1,396 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on NVO. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $78.74 on Monday. The firm’s 50 day moving average price is $97.76 and its two-hundred day moving average price is $117.05. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The firm has a market cap of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.